136 related articles for article (PubMed ID: 27689533)
21. DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy.
Nguyen NT; Pacelli A; Nader M; Kossatz S
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267438
[TBL] [Abstract][Full Text] [Related]
22. PARP1 is required for adhesion molecule expression in atherogenesis.
von Lukowicz T; Hassa PO; Lohmann C; Borén J; Braunersreuther V; Mach F; Odermatt B; Gersbach M; Camici GG; Stähli BE; Tanner FC; Hottiger MO; Lüscher TF; Matter CM
Cardiovasc Res; 2008 Apr; 78(1):158-66. PubMed ID: 18093987
[TBL] [Abstract][Full Text] [Related]
23. PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response.
Kim C; Wang XD; Yu Y
Elife; 2020 Aug; 9():. PubMed ID: 32844745
[TBL] [Abstract][Full Text] [Related]
24. A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.
Makvandi M; Pantel A; Schwartz L; Schubert E; Xu K; Hsieh CJ; Hou C; Kim H; Weng CC; Winters H; Doot R; Farwell MD; Pryma DA; Greenberg RA; Mankoff DA; Simpkins F; Mach RH; Lin LL
J Clin Invest; 2018 May; 128(5):2116-2126. PubMed ID: 29509546
[TBL] [Abstract][Full Text] [Related]
25. In vivo visualization of PARP inhibitor pharmacodynamics.
McDonald ES; Pantel AR; Shah PD; Farwell MD; Clark AS; Doot RK; Pryma DA; Carlin SD
JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33884961
[TBL] [Abstract][Full Text] [Related]
26. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
27. Altered expression of the poly(ADP-ribosyl)ation enzymes in uveal melanoma and regulation of PARG gene expression by the transcription factor ERM.
Molloy-Simard V; St-Laurent JF; Vigneault F; Gaudreault M; Dargis N; Guérin MC; Leclerc S; Morcos M; Black D; Molgat Y; Bergeron D; de Launoit Y; Boudreau F; Desnoyers S; Guérin S
Invest Ophthalmol Vis Sci; 2012 Sep; 53(10):6219-31. PubMed ID: 22915039
[TBL] [Abstract][Full Text] [Related]
28. Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?
Hottiger MO
Expert Opin Ther Targets; 2015; 19(9):1149-52. PubMed ID: 26212149
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
30. Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi.
Fejzo MS; Anderson L; Chen HW; Guandique E; Kalous O; Conklin D; Slamon DJ
Genes Chromosomes Cancer; 2017 Aug; 56(8):589-597. PubMed ID: 28316110
[TBL] [Abstract][Full Text] [Related]
31. Tanshinone I and simvastatin inhibit melanoma tumour cell growth by regulating poly (ADP ribose) polymerase 1 expression.
Zhang Y; Huang J; Huang Y; Zhang S; Wu W; Long H; Duan X; Lai Y; Wu W
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33179075
[TBL] [Abstract][Full Text] [Related]
32. Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma.
Carlucci G; Carney B; Brand C; Kossatz S; Irwin CP; Carlin SD; Keliher EJ; Weber W; Reiner T
Mol Imaging Biol; 2015 Dec; 17(6):848-55. PubMed ID: 25895168
[TBL] [Abstract][Full Text] [Related]
33. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
Wang B; Chu D; Feng Y; Shen Y; Aoyagi-Scharber M; Post LE
J Med Chem; 2016 Jan; 59(1):335-57. PubMed ID: 26652717
[TBL] [Abstract][Full Text] [Related]
34. Recent Progress in the Research on Benzimidazole PARP-1 Inhibitors.
Wu K; Chen M; Peng X; Li Y; Tang G; Peng J; Cao X
Mini Rev Med Chem; 2022; 22(19):2438-2462. PubMed ID: 35319364
[TBL] [Abstract][Full Text] [Related]
35. Poly(ADP-ribose)polymerase activation mediates lung epithelial cell death in vitro but is not essential in hyperoxia-induced lung injury.
Pagano A; Pitteloud C; Reverdin C; Métrailler-Ruchonnet I; Donati Y; Barazzone Argiroffo C
Am J Respir Cell Mol Biol; 2005 Dec; 33(6):555-64. PubMed ID: 16151053
[TBL] [Abstract][Full Text] [Related]
36. PARP2 Is the Predominant Poly(ADP-Ribose) Polymerase in Arabidopsis DNA Damage and Immune Responses.
Song J; Keppler BD; Wise RR; Bent AF
PLoS Genet; 2015 May; 11(5):e1005200. PubMed ID: 25950582
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of arginine ADP-ribosyltransferase 1 reduces the expression of poly(ADP-ribose) polymerase-1 in colon carcinoma.
Tang Y; Wang YL; Yang L; Xu JX; Xiong W; Xiao M; Li M
Int J Mol Med; 2013 Jul; 32(1):130-6. PubMed ID: 23652727
[TBL] [Abstract][Full Text] [Related]
38. Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
Gan A; Green AR; Nolan CC; Martin S; Deen S
Hum Pathol; 2013 Aug; 44(8):1638-47. PubMed ID: 23574784
[TBL] [Abstract][Full Text] [Related]
39. Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models.
Carney B; Carlucci G; Salinas B; Di Gialleonardo V; Kossatz S; Vansteene A; Longo VA; Bolaender A; Chiosis G; Keshari KR; Weber WA; Reiner T
Mol Imaging Biol; 2016 Jun; 18(3):386-92. PubMed ID: 26493053
[TBL] [Abstract][Full Text] [Related]
40. Trapping Poly(ADP-Ribose) Polymerase.
Shen Y; Aoyagi-Scharber M; Wang B
J Pharmacol Exp Ther; 2015 Jun; 353(3):446-57. PubMed ID: 25758918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
